14 Aug 2025
Dr. Farah Husein, Director of Science & Methods at Canada’s Drug Agency, introduces CDA-AMC’s role as a pan-Canadian health organization dedicated to improving coordination, alignment, and value in the drug and health technology system. The presentation outlines the agency’s expanded …...
04 Aug 2025
Latest Developments at INESSS At the 2024 Market Access Canada Summit, Mélanie Caron outlined major updates from INESSS, highlighting legislative changes, process improvements, and strategic priorities shaping Quebec’s drug evaluation and reimbursement landscape. Key Highlights: Bill 15 (2023): Limits hospital …...
14 Aug 2025
Dr. Kendall Jamieson Gilmore, Associate Director of Strategy at NICE, outlines how global collaboration in Health Technology Assessment can accelerate access to innovation, strengthen system readiness, and enhance patient outcomes. The presentation highlights NICE’s recent progress in delivering faster, more …...
23 Jul 2025
At the 2024 Market Access Summit on October 29, Guillaume Couillard, Director General, presented an update on the Patented Medicine Prices Review Board (PMPRB), its evolving mandate, and the development of new guidelines to ensure Canada’s patented drug prices remain …...
07 Apr 2025
The Canadian drug landscape is undergoing a transformative shift, and pharmaceutical manufacturers need a strategic playbook to succeed. Here are seven insider secrets to help you navigate the Canada’s Drug Agency’s (CDA) new mandate: 1. Embrace Real-World Evidence Early …...
07 Apr 2025
In a recent panel discussion on pharmaceutical access, healthcare experts revealed critical insights into how technology could revolutionize healthcare equity. Here are four groundbreaking trends that promise to reshape how Canadians access medical care: Intelligent Telehealth Beyond Urban Centers The …...
22 May 2025
The introduction of Canada’s national PharmaCare program has created a complex environment for pharmaceutical companies developing innovative medicines. Here are three strategic approaches to navigate this uncertain terrain: Proactive Engagement with Policy Makers As the landscape of healthcare continues to …...
19 Jun 2025
Introduction In the rapidly evolving landscape of Canadian healthcare, biosimilars are emerging as a game-changing solution to rising medical costs. With the total biologics market valued at $8 billion and biosimilars representing $1 billion, these innovative medications are reshaping how …...
07 Apr 2025
In the rapidly evolving landscape of healthcare innovation, breakthrough therapies are emerging faster than ever—but there’s a critical bottleneck preventing patients from accessing these life-changing treatments. Enter Outcome-Based Agreements (OBAs), a strategic approach that’s poised to transform how we think …...
Loading...
